Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
08 4월 2024 - 9:05PM
Business Wire
Savara’s Partner, Trillium Health LLC, to
Present Data on the Laboratory Blood Test for Diagnosing aPAP
Company to Host Industry Theater on Pulmonary
Alveolar Proteinosis (PAP) with Two World-Renowned Experts
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
today announced the acceptance of two abstracts for poster
presentation at the American Thoracic Society (ATS) 2024
International Conference, taking place May 17-22, 2024, in San
Diego, CA.
“We look forward to seeing data presented at ATS on the
significant healthcare burden facing aPAP patients, challenges for
diagnosis, and the development of a novel laboratory-based
autoantibody blood test that can provide a definitive diagnosis of
aPAP,” said Matt Pauls, Chair and CEO, Savara. “We are also keen to
increase awareness and understanding of this rare and chronic lung
disease through our Industry Theater with two aPAP experts.”
ATS 2024 Accepted
Abstracts:
Savara 701: Healthcare Burden of Pulmonary Alveolar
Proteinosis Poster Session A26: Improving Outcomes in
Sarcoidosis, Rare Lung Disease and Lung Transplant Poster
Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT
Trillium Health 702: Development of a Novel Laboratory Test
for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of
Individuals At-Risk for Autoimmune Pulmonary Alveolar Proteinosis
(aPAP) Poster Session A26: Improving Outcomes in Sarcoidosis,
Rare Lung Disease and Lung Transplant Poster Discussion Session:
Sunday, May 19, 2024, 9:15-11:15 AM PDT
The abstracts will be published in a supplement of the American
Journal of Respiratory and Critical Care Medicine (AJRCCM) on May
1, 2024. For more details about the ATS International Conference
please visit https://conference.thoracic.org/index.php.
Industry Theater:
Pulmonary Alveolar Proteinosis (PAP): Pathophysiology,
Diagnosis, and Management Sunday, May 19, 2024, 1:15-2:00 PM
PDT
Bruce Trapnell, M.D., M.S. and Tisha Wang, M.D. will provide an
overview of PAP, including the burden of this rare lung disease,
the hallmark signs and symptoms of autoimmune PAP (aPAP), the most
common form of PAP, and the path to diagnosing aPAP.
About aPAP
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung
disease that belongs to a family of distinct rare lung diseases
collectively known as pulmonary alveolar proteinosis (PAP). aPAP
represents about 90% of all patients with PAP. While aPAP can
affect people of any age, race or sex, onset occurs most frequently
in people between the ages of 30 and 40. PAP is characterized by
the build-up of surfactant in the alveoli, or air sacs, of the
lungs. The surfactant consists of proteins and lipids and is an
important physiological substance that lines the inside of the
alveoli to prevent the lungs from collapsing. The root cause of
aPAP is an autoimmune response against GM-CSF, a naturally
occurring protein in the body. Pulmonary macrophages need to be
stimulated by GM-CSF to function properly, but in aPAP, GM-CSF is
neutralized by antibodies against GM-CSF, rendering the macrophages
unable to perform their tasks, including the clearance of
surfactant from the alveoli. In aPAP, the feeling of having trouble
breathing is the most common symptom. People with aPAP can also
experience chronic cough, fatigue, sputum production, reduced
ability to exercise and episodes of fever due to underlying
pulmonary infections.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, molgramostim nebulizer
solution, is an inhaled granulocyte-macrophage colony-stimulating
factor (GM-CSF) in Phase 3 development for autoimmune pulmonary
alveolar proteinosis (aPAP). Molgramostim is delivered via an
investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our
management team has significant experience in rare respiratory
diseases and pulmonary medicine, identifying unmet needs, and
effectively advancing product candidates to approval and
commercialization. More information can be found at
www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma,
LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
Forward-Looking Statements
Savara cautions you that statements in this press release that
are not a description of historical fact are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
the use of words referencing future events or circumstances such as
“expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,”
among others. Savara may not actually achieve any of the matters
referred to in such forward-looking statements, and you should not
place undue reliance on these forward-looking statements. These
forward-looking statements are based upon Savara’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the outcome of
our ongoing and planned clinical trials for our product candidate,
the ability to project future cash utilization and reserves needed
for contingent future liabilities and business operations, the
availability of sufficient resources for Savara’s operations and to
conduct or continue planned clinical development programs, the
ability to successfully develop our product candidate, the risks
associated with the process of developing, obtaining regulatory
approval for and commercializing drug candidates such as
molgramostim that are safe and effective for use as human
therapeutics, and the timing and ability of Savara to raise
additional capital as needed to fund continued operations. All
forward-looking statements are expressly qualified in their
entirety by these cautionary statements. For a detailed description
of our risks and uncertainties, you are encouraged to review our
documents filed with the SEC including our recent filings on Form
8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue
reliance on forward-looking statements, which speak only as of the
date on which they were made. Savara undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408391675/en/
Savara Inc. IR & PR Anne Erickson Chief Business
Officer anne.erickson@savarapharma.com (512) 851-1366
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024